Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1Phase 3 1

Status

Completed 7Withdrawn 1

Sponsor Class

OTHER 17INDUSTRY 8OTHER_GOV 1

Study Type

Interventional 7Observational 1

Sponsor

Cancer Type

Gastrointestinal 4Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 2Uveal Melanoma 1Polyps 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Colonic Neoplasms 1Colonic Diseases 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × Polyethylene Glycols × Clear all
NCT05174845 2022-05-31

Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia

Norgine

Completed
13,393 enrolled
Gastrointestinal

Colonic Diseases, Colonic Neoplasms

NCT01910012 2020-10-01

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Polaris Group

Phase 2 Completed
43 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02893748 2019-09-23

HyGIeaCare Prep vs Split-dose PEG Prep Prior to Colonoscopy

HyGIeaCare, Inc.

Phase NA Withdrawn

Neoplasms, Polyps

NCT01287585 2019-09-06

ADI-PEG 20

Polaris Group

Phase 3 Completed
636 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01910025 2018-09-18

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Polaris Group

Phase 2 Completed
18 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT02006030 2018-09-04

TACE

Polaris Group

Phase 2 Completed
30 enrolled
Gastrointestinal

Liver Neoplasms

NCT02101593 2016-03-04

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Polaris Group

Phase 1 Completed
8 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01665183 2016-02-25

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Polaris Group

Phase 1 Completed
8 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡